Status: Not yet recruiting
A Safety Study of 212Pb-Pentixather Radioligand Therapy
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.
Participants needed: 20
Trial details
Phase: Early Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Yusuf MendaUpdated: Jul 8, 2025Locations: 1
Eligibility criteria
ability to provide independent consent [+5]
major surgery within 4 weeks of consent [+9]